{"database": "lobbying", "table": "lobbying_activities", "rows": [[3200831, "34a06cb7-ee48-4a6b-9f84-7a59a2e86f40", "Q2", "TRUSYNERGY", 401107715, "BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.)", 2024, "second_quarter", "PHA", "Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; MCM PRV; SUPER BUGS Act", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2024-07-18T16:44:46-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3200831"], "units": {}, "query_ms": 60.52312802057713, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}